Publications by authors named "F Oberti"

Claim this Profile
E
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.
Thierry Thévenot, Laure Elkrief, Christophe Bureau, Edouard Bardou-Jacquet, Isabelle Rosa, Frédéric Oberti

J Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.
Héloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, Mohamed Bouattour, Eric Assenat, Frédéric Oberti

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.
Manon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, Mohamed Bouattour, Julien Edeline, Frédéric Oberti

Liver Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.
Eric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, Amaddeo Giuliana, Thomas Decaens, Frédéric Oberti

Eur J Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial.
Jean-Paul Cervoni, Delphine Weil, Maxime Desmarets, Adrien Lannes, Louis D'Alteroche, Frédéric Oberti

Lancet Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis